Your browser doesn't support javascript.
loading
AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival.
Cosimo, Emilio; Tarafdar, Anuradha; Moles, Michael W; Holroyd, Ailsa K; Malik, Natasha; Catherwood, Mark A; Hay, Jodie; Dunn, Karen M; Macdonald, Alan M; Guichard, Sylvie M; O'Rourke, Declan; Leach, Michael T; Sansom, Owen J; Cosulich, Sabina C; McCaig, Alison M; Michie, Alison M.
Afiliación
  • Cosimo E; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Tarafdar A; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Moles MW; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Holroyd AK; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Malik N; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Catherwood MA; Department of Haematology, Belfast City Hospital, Belfast, United Kingdom.
  • Hay J; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Dunn KM; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Macdonald AM; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Guichard SM; Forma Therapeutics, Watertown, Massachusetts.
  • O'Rourke D; Department of Histopathology, Belfast City Hospital, Belfast, United Kingdom.
  • Leach MT; Department of Haematology, Gartnavel General Hospital, Glasgow, United Kingdom.
  • Sansom OJ; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  • Cosulich SC; Cancer Research UK Beatson Institute, Garscube Estate, Glasgow, United Kingdom.
  • McCaig AM; Bioscience, Oncology, IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Michie AM; Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.
Clin Cancer Res ; 25(5): 1574-1587, 2019 03 01.
Article en En | MEDLINE | ID: mdl-30559170
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptores de Antígenos de Linfocitos B / Leucemia Linfocítica Crónica de Células B / Inhibidores de Proteínas Quinasas / Proteínas Proto-Oncogénicas c-akt / Proteína Forkhead Box O1 / Diana Mecanicista del Complejo 2 de la Rapamicina Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Asunto principal: Receptores de Antígenos de Linfocitos B / Leucemia Linfocítica Crónica de Células B / Inhibidores de Proteínas Quinasas / Proteínas Proto-Oncogénicas c-akt / Proteína Forkhead Box O1 / Diana Mecanicista del Complejo 2 de la Rapamicina Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans / Male Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido